Health
Secukinumab Has High Retention Rate in Real-World Psoriatic Arthritis Study – AJMC.com Managed Markets Network
New real-world data shows 64% of patients with psoriatic arthritis who had previously been on a biologic stayed on secukinumab for the duration of the study.
A new study suggests secukinumab (Cosenytx) has a high retention rate among biologic-experienced patients with psoriatic arthritis (PsA) in real-world settings, and also produces minimal serious side effects.
The research is important because previous data on the real-world usage of the recombinant human monoclonal antibody has been scarce. The drug, which targets interleukin-17A, has been approved for the treatment of PsA since 2015 in Europe and 2016 in the United States.
A team of Greek inv…
-
Noosa News16 hours agoInquest into Rosemarie Campbell’s death three days after gastric bypass surgery hears of ‘massive loss’ to family
-
Noosa News7 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General13 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965
-
General23 hours agoIndonesia airdropped aid for Palestinians in Gaza, but experts question its effectiveness